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It is of crucial importance to detect the kinetic, metabolic and toxicity (ADME-Tox)
profiles of new drug candidates in an early stage of drug development. The costs and
the use of animals can be significantly reduced when the in vivo behavior of new
 chemical entities is accurately predicted by in vitro methods earlier on in the
 development process. Therefore, the role of in vitro systems to predict these profiles
is essential. Many in vitro systems have been developed the last decades,1 however,
a significant number of drugs is still withdrawn in a late stage of drug development.2,
3 As mentioned in Chapter 1, the aim of this thesis was to develop a new in vitro
 system which can be used to gain more information about the ADME-Tox properties
of new drug candidates in an early stage. The in vitro system which has been  realized
incorporates precision-cut tissue slices in a microfluidic-based biochip. The use of
 microfluidic technology for the development of in vitro systems has many  advantages
compared to conventional incubation systems.4 The main advantage is the ability to
control the cell’s microenvironment by introducing a continuous flow which enables
the establishment of steady-state conditions. 
Various microfluidic systems have been developed with liver cells incorporated on
chip, with the aim to measure the biotransformation of drugs in the human liver.
Chapter 2 reviews the currently available microfluidic-based in vitro models for liver
metabolism and toxicity profiling and discusses their respective advantages and
 disadvantages. From this literature review, it became clear that only two of these
 models, primary hepatocytes and precision-cut liver slices (PCLS), can adequately
 represent liver metabolism in vivo. As PCLS retain an intact architecture with all cell
types present in their native configuration and intact cell-cell contacts, they seem
 eminently suitable for toxicity studies. 
The first microfluidic-based system incorporating rat PCLS is presented in
 Chapter 3. A polydimethylsiloxane device is described, allowing continuous  supply
of medium by perfusion to rat liver slices for 24-h incubation. Care was taken that the
pH, oxygen concentration, and temperature remain constant during the incubation.
For this reason aeration windows were integrated into the chip to act as “breathing”
membranes. As it was crucial to first verify the performance of the newly developed
system by comparison with validated conventional systems, we compared the
 viability and metabolic function of PCLS in the biochip with PCLS incubated in a
conventional well-plate system. The viability and metabolic activity for the tested
substrate were not significantly different in both systems, indicating that PCLS remain
functionally intact in the biochip for at least 24 h.
An advantage of the continuous flow is that the outflow can be directly and
 continuously analyzed for metabolite formation. The development of an on-line
 analysis system by coupling the biochip with an HPLC with ultraviolet detection is
demonstrated in Chapter 4. The design of the device results in a low medium-
 volume-to-slice-volume ratio, thereby resulting in high concentrations of  metabolites







in the outflow. This automated system makes it possible to repeatedly expose a slice
to substrates. For example, PCLS were incubated four times with 7- hydroxycoumarin
for 2-h periods, with intervals of 4 hours between incubations. An immediate
 production of metabolites was observed, and the maintenance of the viability and
metabolic activity of the slice was demonstrated. It will be interesting to use this
 system in the future to try to measure metabolic circadian rhythms. In this chapter, the
on-line system was also used to study inhibitory drug-drug interaction. The
 concentration of inhibitor in this case was increased in a stepwise fashion. Only three
slices were used in one experiment, allowing the determination of the dissociation
constant for inhibitor binding using a minimal amount of tissue. In the future, the
time-dependent induction of metabolism may be studied in this device. The system
is also ideal for studies on scarce tissue, like human material. Another great potential
of this system is the ability to detect unstable metabolites. This was demonstrated by
the measurement of the formation of diclofenac acyl glucuronide, an unstable
 metabolite formed by the liver from the drug, diclofenac. Acyl glucuronide
 metabolites are considered to be reactive metabolites and thus cause toxicity. These
reactive metabolites are difficult to detect with conventional systems due to their
 chemical instability. It was shown that the on-line analysis system is able to measure
these metabolites directly after their formation at a relatively high concentration,
which may be useful for the prediction of the formation of other reactive  metabolites
as well. In future, it would be interesting to couple this on-line analysis system directly
to a mass spectrometer, allowing the simultaneous on-line analysis and identification
of metabolites.
In the first chapters, the maximum slice incubation time was 24 hours. In  Chapter
5 this incubation time was extended to 72 hours for rat PCLS by embedding slices in
a hydrogel matrix. When slices were suspended in solution in the biochip, the  viability
was well maintained for 72 hours; however, the metabolic capacity of the slices both
for phase I and phase II metabolism decreased over time. It was found that PCLS had
attached themselves to the upper filter of the microchamber after prolonged
 incubations (>24 hours). The embedding of PCLS in a hydrogel significantly
 improved the maintenance of metabolism. Matrigel was used as hydrogel, which is
a basement membrane matrix. The embedding prevented the attachment of the PCLS
onto the polycarbonate filter at the outflow of the chamber. In addition, by
 supplementing the WME medium with bovine serum, dexamethasone and insulin,
the capacity for phase II metabolism was fully maintained at the level of fresh slices
for 72 hours. However, phase I metabolism of 7-ethoxycoumarin still decreased over
time in a manner analogous to that in well plates, as was also found by others.5-7 This
is probably due to an unoptimized medium composition and the lack of endogenous
stimuli to activate transcription factors involved in the expression of the phase I
 metabolizing enzymes, rather than damage incurred in the incubation system. For
further research, the addition of a low concentration of cytochrome P450 inducers
might result in a more stable phase I metabolism.8
It is now generally accepted that for proper prediction of drug metabolism in man,
human in vitro preparations are preferred, because of the well-known species
 differences in drug metabolism.9 PCLS can be prepared from surgical liver waste
 tissue obtained after liver transplantation, or after partial hepatectomy (resection of
liver parts to remove tumors).10 In addition, it is also possible to prepare slices from
diseased tissue, thereby enabling the study of pathophysiological processes. In
Chapter 6 the successful incorporation of healthy human liver slices in the microchip
was demonstrated. The viability was determined by morphological evaluation and
enzyme leakage tests. The metabolic activity was assessed by incubating the slices
with four different substrates, testosterone, lidocaine, 7-ethoxycoumarin and 7-
 hydroxycoumarin, covering a wide range of phase I and phase II metabolism
pathways. The results showed that human PCLS function similarly to those  incubated
in the conventional well plate system, which also for human PCLS correlates well
with the in vivo situation.11 The flow introduced in the microfluidic device did not
 resulted in different metabolic activities or lower viability. We conclude, therefore,
that human liver slices can also be incubated in the biochip for metabolism and
 toxicity studies. 
The incorporation of precision-cut rat intestinal slices was also established, as
shown in Chapter 7. This is the first example of intestinal slices incubated in a
 microfluidic device. The slices were incubated with three different substrates, and
high metabolic activity was observed for 3 hours of incubation, comparable to the
activity in well plates. In contrast to liver slices, which remain viable for 72 h,
 intestinal slices partially lose their metabolic function and ATP content after 24 h of
incubation in well plates. Therefore, in future studies, it would be interesting to test
if intestinal slices retain their viability during longer perifusion in the biochip.
 However, it should be noted that the apical and basolateral sides of the intestinal  tissue
were not perfused separately in our system. It would also be interesting to develop a
 device which does separate the two sides of the intestine, to be able to perform ab-
sorption studies. Conventional system exists in which the two sides can be separated,
so- called Ussing chamber.12 It would be interesting to develop an Ussing chamber
on chip to investigate the transport and metabolism of drugs in very specific regions
of the  intestine.
Due to the continuous flow, the outflow of a chamber containing the metabolites
and products formed by a slice can be directed to the inlet of another chamber which
also contains a slice. It thus becomes possible to measure interorgan effects,
 something which is not possible in well plates. Two slices from different organs can
be placed in one well; however, mutual interaction can take place, and it is  impossible
to conclude which organ was responsible for an observed effect. To verify whether
Chapter 9
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such a sequential perifusion of slices would affect the functioning of the slices, two
slices from the same organ were first sequentially perifused with model substrates. No
significant differences in the specific metabolic rates resulted when one or two slices
were perifused. Thereafter, sequential perifusion of an intestinal slice and a liver slice
with model substrates showed that liver slices functioned normally. Apparently, the
excreted products from the intestine did not affect the liver metabolism, indicating no
interorgan effects for these substrates. Interestingly, interplay between intestine and
liver could be demonstrated for the regulation of bile acid synthesis by primary bile
acids. After exposure to the bile acid chenodeoxycholic acid, a significant down
 regulation of CYP7A1 in the liver slice occurred. This could be ascribed to the bile
acid-induced release of fibroblast growth factor 15 (FGF15) by the intestine, which
was directed by the medium flow towards the liver slice. The enzyme, CYP7A1, is
responsible for the synthesis of bile acids in the liver, and is known to be regulated
by FGF15.13 This bile acid regulation pathway showed the potential of the biochip
system to investigate interorgan effects.
Until now, only liver and intestinal slices have been incorporated in the biochip.
As it is also possible to produce precision-cut slices from other organs such as lung
and kidney,11 this biochip technology offers the potential to study the effect of liver
metabolites on these tissues as well, or vice versa. The influence of metabolites
 excreted into the bile of the liver on the intestine can also be studied with the biochip.
By integrating multiple organ slices on chip, the in vivo situation is more closely
 approached than when cell monocultures are employed.
All the experiments were carried out with a biochip made from polydimethyl -
siloxane (PDMS). This is an ideal elastomer for rapid prototyping during the
 development of the biochip; however, the adsorption/absorption of hydrophobic
 compounds is an important disadvantage.14 This problem was observed with the
 incubation of PCLS with testosterone in Chapter 6. In Chapter 8, we set out to
 investigate whether other materials, such as plastics, could replace PDMS as
 fabrication material. In this study, the thermoplastic polymers, polystyrene (PS),
 polycarbonate (PC), polymethylmethacrylate (PMMA), and cyclic olefin copolymer
(COC), were tested. These polymers were selected because of their reported
 biocompatibility and because chips can be fabricated using a hot embosser, which is
superior to PDMS casting for producing large numbers of biochips in a shorter period
of time. In their native form, these plastic substrates are also hydrophobic. However,
the surface could be modified by oxidation using UV ozone or oxygen plasma
 treatment, resulting in more hydrophilic surfaces which remain stable for up to 4
weeks. PC, PS and COC chips showed no significant adsorption of testosterone and
7-ethoxycoumarin and their metabolites. As a model to test the biocompatibility of
these plastics after treatment, a liver cell line (HepG2) was cultured on the UV ozone
treated plastics. The cells were able to grow on all treated substrate surfaces after







coating with collagen. Hardly any dead cells were found (~2%) on PC, PS, and COC.
This indicates that the plastics are not toxic after treatment. In contrast, 25% of the
cells were non-viable on PMMA, indicating a potential effect of the plastic or the
UV ozone treatment on cell viability. We concluded that PC, PS and COC are all
 suitable to fabricate biochips with low adsorptive characteristics and high
 biocompatibility. Since PS is less resistant to the organic solvents used, for example,
for on-line introduction of liquid chromatography on chip, the use of PC or COC is
recommended. Of these two, COC has the additional advantage of exhibiting a lower
autofluorescence compared to PC,15 which is beneficial for optical imaging.  
A biochip made from COC with aeration windows to control the pH and oxygen
concentration in medium would be the best option for further studies. This low-cost
device could be produced in batch, would not adsorb hydrophobic compounds if
 surface-oxidized, and could be used in the on-line analysis system. Multiple  chambers
containing different slices could be sequentially perfused in a manner similar to the
PDMS device. Another interesting aspect for further studies would be the integration
of components for the generation of concentration gradients16 and other components
such as a pump17 for medium flow or detectors for on-chip monitoring of pH18 or
 metabolite formation19. 
The successful development of a microfluidic-based in vitro system with
 perifusion of liver and intestinal slices to study drug metabolism has been realized.
A stable incubation environment, e.g. pH, oxygen concentration and nutrients, was
achieved by introducing a low flow rate. Liver slices could be maintained viable for
72 hours and intestinal slices for at least 3 hours. Although it was previously  suggested
that the introduction of medium flow in cell or tissue culture would promote longer
viability,20, 21 this has not yet been confirmed in our system. Possible causes for this
and their resolution remain to be elucidated. A limitation of the system is the  possible
adsorption/absorption of hydrophobic compounds onto the PDMS material;  however,
by producing the chip in COC, this can be prevented. This newly developed in vitro
system is very promising for gaining better insight into possible interorgan effects.
Moreover, earlier detection of unstable metabolites is made feasible with the on-line
HPLC system. As an alternative to well plates, this system will contribute to a better
prediction of metabolism and toxicity in man with a concomitant reduction in the use
of experimental animals. The microfluidic biochip thus has the potential to
 significantly impact drug metabolism and toxicology studies of novel chemical
 entities. 
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